Related Experiment Video
Updated: Jul 7, 2026
Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023
Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth
Ling Zhang1, Lifang Gao, Yang Li
1Prostate Diseases Prevention and Treatment Research Center and Department of Pathophysiology, School of Basic Medicine, Jilin University, Changchun, PR China.
Purpose:
Persistent activation of signal transducers and activators of transcription 3 (Stat3) and its overexpression contribute to the progression and metastasis of several different tumor types. For this reason, Stat3 is a reasonable target for RNA interference-mediated growth inhibition. Blockade of Stat3 using specific short hairpin RNAs (shRNA) can significantly reduce prostate tumor growth in mice. However, RNA interference does not fully ablate target gene expression in vivo, owing to the idiosyncrasies associated with shRNAs and their targets. To enhance the therapeutic efficacy of Stat3-specific shRNA, we applied a combination treatment involving gene associated with retinoid-IFN-induced mortality 19 (GRIM-19), another inhibitor of STAT3, along with shRNA.
Experimental Design:
The coding sequences for GRIM-19, a cellular STAT3-specific inhibitor, and Stat3-specific shRNAs were used to create a dual expression plasmid vector and used for prostate cancer therapy in vitro and in mouse xenograft models in vivo.
Results:
The coexpressed Stat3-specific shRNA and GRIM-19 synergistically and more effectively suppressed prostate tumor growth and metastases when compared with treatment with either single agent alone.
Conclusion:
The simultaneous use of two specific, but mechanistically different, inhibitors of STAT3 activity exerts enhanced antitumor effects.
Insights
Combining short hairpin RNA (shRNA) targeting Signal Transducer and Activator of Transcription 3 (Stat3) with GRIM-19, a STAT3 inhibitor, synergistically reduced prostate tumor growth and metastasis in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Persistent Signal Transducer and Activator of Transcription 3 (STAT3) activation and overexpression drive tumor progression and metastasis.
- STAT3 is a validated therapeutic target for cancer growth inhibition.
- RNA interference (RNAi) using short hairpin RNA (shRNA) can inhibit STAT3, but complete ablation of gene expression in vivo is challenging.
Purpose of the Study:
- To enhance the therapeutic efficacy of STAT3-specific shRNA for prostate cancer treatment.
- To investigate the synergistic effects of combining STAT3-specific shRNA with GRIM-19, a STAT3 inhibitor.
Main Methods:
- A dual expression plasmid vector was engineered to coexpress STAT3-specific shRNA and GRIM-19.
- The dual expression vector was utilized for prostate cancer therapy in vitro and in mouse xenograft models.
Main Results:
- Coexpression of STAT3-specific shRNA and GRIM-19 demonstrated synergistic suppression of prostate tumor growth.
- Combined treatment significantly inhibited tumor metastasis more effectively than single-agent treatments.
- The combination therapy showed enhanced antitumor effects compared to either shRNA or GRIM-19 alone.
Conclusions:
- Simultaneous administration of two mechanistically distinct STAT3 inhibitors enhances antitumor effects.
- Combination therapy targeting STAT3 represents a promising strategy for prostate cancer treatment.
- This approach offers a potential method to overcome limitations of single-agent RNAi therapies.
